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Abstract
Metabolic reprogramming is a prominent feature of clear cell renal cell carcinoma (ccRCC). Here 
we investigated metabolic dependencies in a panel of ccRCC cell lines using nutrient depletion, 
functional RNAi screening and inhibitor treatment. We found that ccRCC cells are highly sensitive 
to the depletion of glutamine or cystine, two amino acids required for glutathione (GSH) synthesis. 
Moreover, silencing of enzymes of the GSH biosynthesis pathway or glutathione peroxidases, 
which depend on GSH for the removal of cellular hydroperoxides, selectively reduced viability of 
ccRCC cells but did not affect the growth of non-malignant renal epithelial cells. Inhibition of 
GSH synthesis triggered ferroptosis, an iron-dependent form of cell death associated with 
enhanced lipid peroxidation. VHL is a major tumour suppressor in ccRCC and loss of VHL leads 
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to stabilisation of hypoxia inducible factors HIF-1α and HIF-2α. Restoration of functional VHL 
via exogenous expression of pVHL reverted ccRCC cells to an oxidative metabolism and rendered 
them insensitive to the induction of ferroptosis. VHL reconstituted cells also exhibited reduced 
lipid storage and higher expression of genes associated with oxidiative phosphorylation and fatty 
acid metabolism. Importantly, inhibition of β-oxidation or mitochondrial ATP-synthesis restored 
ferroptosis sensitivity in VHL reconstituted cells. We also found that inhibition of GSH synthesis 
blocked tumour growth in a MYC-dependent mouse model of renal cancer. Together, our data 
suggest that reduced fatty acid metabolism due to inhibition of β-oxidation renders renal cancer 
cells highly dependent on the GSH/GPX pathway to prevent lipid peroxidation and ferroptotic cell 
death.
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Introduction
Renal cell carcinoma (RCC) is a devastating disease due to frequent metastasis formation 
and resistance to conventional or targeted therapies 45. Clear cell renal cell carcinoma 
(ccRCC) is the most common type of RCC and both hereditary and sporadic ccRCC are 
strongly associated with mutations in the von Hippel Lindau (VHL) gene 28 that lead to the 
stabilisation of the hypoxia inducible factors (HIF-1α and HIF-2α) 23, 34. As metabolic 
reprogramming is a major feature of ccRCC tumours 8, 16, 25, targeting metabolic 
processes could be a successful strategy in the treatment of this disease.
One by-product of the enhanced metabolic activity of cancer cells is the increased 
generation of reactive oxygen species (ROS), which are generated, amongst others, by the 
complexes of the mitochondrial electron transport chain (ETC) 38. While high levels of ROS 
are detrimental to cell viability, ROS can also promote cell transformation and tumour 
development, for example by participating in signalling processes 46. There is now 
substantial evidence that oncogene activation provokes oxidative stress but also induces anti-
oxidant pathways to prevent the accumulation of ROS and avoid cell damage 7, 22. 
Glutathione, the major non-enzymatic antioxidant in cells, is formed by the sequential 
condensation of glutamate, cysteine and glycine. In addition to its direct anti-oxidant 
function 22, GSH is a co-substrate of glutathione peroxidases (GPX), a class of 
selenocysteine-containing enzymes that reduce hydroperoxides, including hydrogen 
peroxide (H2O2) and lipid peroxides 6. While most GPX proteins reduce soluble 
hydroperoxides, GPX4 can also target peroxidised acyl-groups found in membrane lipids 6. 
Impaired GSH synthesis or inhibition of GPX4 activity has been linked to the induction of 
ferroptosis, an iron-mediated form of cell death caused by the accumulation of lipid 
peroxides 12, 53.
In this study, we investigated metabolic liabilities of ccRCC cells. Using selected amino acid 
depletion, RNAi screening and inhibitor treatment, we found that ccRCC cells are highly 
dependent on GSH biosynthesis and GPX function to prevent the induction of ferroptosis. 
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Moreover, reconstitution of functional VHL prevented the induction of ferroptosis in 
response to inhibition of GSH synthesis in ccRCC cells, by reverting cells back to an 
oxidative metabolism and increasing fatty acid degradation through β-oxidation. We also 
found that inhibition of GSH biosynthesis efficiently blocked tumour growth in a mouse 
model of renal cancer. Our results suggest that targeting GSH biosynthesis and GPX activity 
could be a promising strategy for the treatment of ccRCC.
Results
Glutathione biosynthesis is essential in renal cancer cells
To establish metabolic dependencies in renal cancer, we first exposed four ccRCC cell lines 
(RCC4, UMRC2, A498 and 769-P) either to full medium or medium deprived of glutamine 
or cystine, the dipeptide precursor for intracellular cysteine. All cell lines showed severe 
growth inhibition when cultured in restricted media (Fig. 1A). Glutamine and cysteine are 
precursors for the synthesis of glutathione, a major cellular antioxidant. We therefore 
investigated whether glutamine and cystine deprivation could be rescued by providing cells 
with exogenous antioxidants. Inhibition of cell proliferation caused by glutamine starvation 
was not affected by the addition of N-acetylcysteine (NAC), (2,2,6,6-
Tetramethylpiperidin-1-yl)oxyl (TEMPO) or cysteine (Fig. 1B). Furthermore, the reduction 
in cell number caused by treatment with BPTES, an allosteric inhibitor of glutaminase 1 
(GLS1), was only partially rescued by addition of NAC in RCC4 or 786-O cells (Fig. S1A). 
In contrast, cell number reduction caused by cystine depletion was consistently rescued by 
addition of NAC or cysteine in several ccRCC cell lines (Fig. 1C), while TEMPO, a mimetic 
of mitochondrial superoxide dismutase, only had a minor effect in one of the cell lines used. 
Together these results suggest that renal cancer cells are highly dependent on exogenous 
glutamine and cystine to feed essential metabolic pathways. Moreover, cystine uptake seems 
to be rate-limiting for the maintenance of the intracellular cysteine pool, which is required 
for protein synthesis and antioxidant generation. Our results also suggest that de novo 
synthesis of cysteine via the transsulfuration pathway cannot substitute for cystine uptake. 
We next investigated whether enzymes involved in glutamine and cystine uptake and the 
GSH biosynthesis pathway are deregulated in renal cancer. Analysis of gene expression data 
showed that genes coding for the Na+-dependent glutamine transporter (SLC1A5) and a 
component of the cystine-glutamate antiporter XCT (SLC7A11) are upregulated in ccRCC 
tumours (Fig. S1B and C). Moreover, the genes coding for subunits of the γ-
glutamylcysteine synthetase (GCLM and GCLC) are also highly expressed in renal tumours 
compared to normal renal tissue (Fig. S1D and E).
We next investigated whether siRNA-mediated silencing of transporters required for the 
uptake of glutamine and cystine or components of the GSH synthesis and regeneration 
pathway had an effect on the viability of renal cancer cells. Interestingly, silencing of 
SLC1A5, SLC7A11, glutathione reductase (GSR), glutaminase (GLS), GCLC and 
glutathione synthase (GSS) resulted in a strong reduction in cell number in several ccRCC 
cell lines (Fig. 1D and E). This was accompanied by a substantial reduction in cellular GSH 
levels (Fig. 1F), supporting the importance of GSH maintenance in these cells.
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Functional screen identifies glutathione peroxidases as essential genes in renal cancer
To obtain a more comprehensive insight into metabolic dependencies of renal cancer cells, 
we performed an siRNA screen targeting 230 metabolic enzymes, nutrient transporters and 
regulators of metabolism in a subset of renal cancer cell lines 17. Cells were cultured for 96 
hours after transfection and numbers of remaining cells were used to calculate z-scores for 
each gene (supplementary Table 1). Ranking of averaged z-scores indicated that all cell lines 
are highly sensitive towards depletion of the MYC proto-oncogene (Fig. 2A and B), which 
has been shown repeatedly to be essential for the proliferation of ccRCC cells 20, 47. 
Moreover, depletion of the glycolytic enzyme ALDOA also caused a strong reduction in cell 
number in all cell lines tested (Fig. 2A and B). This is not surprising as enhanced glycolysis 
is an important feature of ccRCC 43. In addition, we found that silencing of DHCR24, the 
gene coding for an enzyme in the cholesterol biosynthesis pathway, also reduced cell 
numbers in renal cancer cells (Fig. 2A and B). While increased levels of compartmentalised 
cholesterol and cholesterol esters have been found in renal tumours compared to normal 
kidney 18, a clear connection between cholesterol metabolism and renal cancer development 
has not yet been established 14. Among the top ranking genes were also two genes coding 
for glutathione peroxidases, GPX3 and GPX4 (Fig. 2A and B).
GPX4 targets phospholipid hydroperoxides within membranes and lipoproteins 6. GPX3 is a 
secreted protein that is produced by epithelial cells of the proximal renal tubules 1. It has 
been shown that GPX3 is induced by hypoxia 4 but its role in renal cancer has not been 
explored in detail. Finally, silencing of G6PD, the gene coding for the first NADPH 
producing enzyme within the pentose phosphate pathway (PPP), was also detrimental to 
most ccRCC cell lines (Fig. 2A and B). This is consistent with previous findings 
demonstrating that fructose-1,6-bisphosphatase 1 (FBP1) restrains ccRCC cell proliferation 
by interfering with PPP activity 32. As NADPH is an essential cofactor for the synthesis and 
regeneration of GSH, this finding also further supports the importance of GSH for ccRCC 
cell survival.
We also confirmed the screen results by showing that individual silencing of MYC, G6PD, 
DHCR24, GPX3 and GPX4 significantly reduces cell numbers in several renal cancer cell 
lines (Fig. 2C). Moreover, we found that MYC, GPX4 and G6PD are upregulated in ccRCC 
tumours compared to normal kidney (Fig. S2A-C), further supporting the importance of 
these genes in ccRCC development.
Inhibition of GSH synthesis induces ferroptosis in renal cancer cells
The results obtained so far indicate that ccRCC cells are highly sensitive to the disruption of 
the GSH biosynthesis and regeneration pathway or depletion of specific GPX enzymes. 
Inhibition of cystine uptake or inhibition of GPX4 has been linked to ferroptosis, caused by 
the accumulation of lipid hydroperoxides (13 and Fig. 3A). We therefore investigated 
whether inhibition of cystine uptake and GSH synthesis could cause ferroptosis in ccRCC 
cells. Inhibition of cystine import using the XCT-inhibitor Erastin resulted in a robust cell 
number reduction in RCC4 and 786-O cells in a dose dependent manner (Fig. 3B). This was 
alleviated by treatment with ferrostatin-1 (fer-1), a lipophilic small molecule antioxidant that 
was identified as a selective inhibitor of ferroptosis 12. Similarly, reduction in cell number in 
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response to treatment with L-buthionine-S,R-sulfoximine (BSO), an irreversible inhibitor of 
γ-cysteine synthetase, was partially rescued by fer-1 treatment (Fig. 3C). We also confirmed 
that loss of cell viability caused by silencing of SLC7A11 could be restored by treatment 
with fer-1 (Fig. 3D).
We next investigated the effect of BSO treatment on cellular GSH levels. This analysis 
showed that even low concentrations of this drug (25-50 μM) already cause a substantial 
reduction in GSH after 24 hours of treatment. A further reduction of GSH levels was 
achieved by lethal BSO concentrations (100 μM and higher) (Fig. 3E). Nevertheless, the low 
levels of residual GSH detected after treatment with 50 μM of BSO were sufficient to 
maintain cell viability in the presence of an oxidative insult, as demonstrated by the 
treatment with H2O2 (Fig. 3F). This suggests that renal cancer cells maintain a large spare 
capacity in their GSH production and that GSH levels have to be reduced below a certain 
threshold before cell viability is compromised.
Restoration of pVHL function induces resistance to ferroptosis in renal cancer cells
To investigate the molecular basis for the high sensitivity of ccRCC cells towards induction 
of ferroptosis, we used derivatives of the VHL-deficient RCC4 cell line that were engineered 
to re-express wild type pVHL or an empty vector (RCC4-VHL and RCC4-EV) 28, 33. In 
ccRCC cells, restoration of pVHL function blocks tumour formation but does not alter cell 
proliferation in vitro 28, 33.
Immunoblotting showed that VHL-reconstituted cells express lower levels of HIF-1α and 
HIF-2α proteins (Fig. 4A) and display reduced mRNA levels of the HIF-target genes 
VEGFA and PDHK1 (Fig. 4B), confirming the functional restoration of pVHL-dependent 
regulation of HIF activity in these cells. Moreover, VHL reconstitution also reduced serine 
473 phosphorylation of AKT and serine 235/236 phosphorylation of pS6 (Fig. 4C). We also 
observed a strong upregulation of basal and maximal respiration as well as enhanced spare 
capacity and mitochondrial ATP production, which is consistent with a reversal of the 
glycolytic phenotype that is established by HIF and AKT activation in VHL mutant renal 
cancer cells (Fig. 4D).
VHL-isogenic cells were also subjected to siRNA screening and differential z-score analysis 
identified those genes that are selectively required in EV cells. Among the VHL-mutant 
specific targets was SLC16A3, the gene coding for the lactate transporter MCT4, which has 
been shown previously to be essential for ccRCC cell survival 19. Moreover, DHCR24, 
GPX4 and GPX3 were also among the genes for which silencing had a greater effect in 
VHL-deficient cells (Fig. 4E).
We next asked whether VHL reconstitution alters the sensitivity of cells towards inhibition 
of GSH synthesis. While treatment with Erastin caused a robust reduction in cell number in 
VHL-deficient cells, which was almost completely blocked by fer-1 treatment, VHL-
restored cells were largely insensitive towards treatment with this compound (Fig. 4F). This 
effect was not due to differential expression of the XCT-transporter, as expression of 
SLC7A11 mRNA was similar in both cell lines (Fig. S3A). Similarly, treatment with BSO 
efficiently reduced cell numbers in empty vector cells, while leaving VHL-restored cells 
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largely unaffected. The effect of BSO on empty vector cells was also completely blocked by 
addition of fer-1 (Fig. 4G).
We also confirmed that VHL-deficient and restored cells contain similar levels of 
intracellular GSH and that Erastin and BSO efficiently depleted GSH levels in both cell lines 
(Fig. S3B). In addition, while sub-lethal concentrations of BSO increased the sensitivity of 
VHL-deficient cells towards oxidative stress induced by H2O2 treatment, VHL-restored cells 
showed higher resistance towards oxidative stress both in the absence and presence of BSO 
(Fig. 4H). Together, these results demonstrate that VHL reconstitution decreases the 
sensitivity of renal cancer cells towards oxidative stress and the induction of ferroptosis in 
response to inhibition of GSH synthesis.
Increased lipid peroxidation causes ferroptosis in VHL-deficient renal cancer cells
A central mechanism of ferroptosis is the accumulation of oxidised lipids produced by the 
cytoplasmic labile iron pool (Fe2+) via the Fenton reaction 13 and through the function of 
Fe-dependent lipoxygenases 54. In agreement with this hypothesis, we found that VHL-
deficient renal cancer cells showed enhanced lipid peroxidation in response to Erastin 
treatment (Fig. 5A).
To address the mechanism underlying the differential sensitivity of VHL-isogenic cells 
towards ferroptosis, we first determined total fatty acid composition derived from all lipid 
species in RCC4-EV and RCC4-VHL cells. We found that the relative proportion of 
saturated fatty acids (SFA), mono-unsaturated fatty acids (MUFA) and poly-unsaturated 
fatty acids (PUFA) (the latter being more susceptible to peroxidation) in the total lipid pool 
were similar in both cell lines (Fig. 5B). Nevertheless, when we stained for neutral lipids 
using Nile Red, we found that numbers, size and intensity of lipid droplets (LD) are strongly 
reduced in VHL-restored cells compared to their VHL deficient counterparts (Fig. 5C and 
D). Extensive lipid storage is an important feature of ccRCC and high levels of LD are found 
in renal tumours compared to normal kidney 40. Moreover, hypoxia induces lipid uptake and 
the formation of LD via a HIF-1α-dependent mechanism 2. This suggests that the high 
abundance of LD found in RCC4-EV cells could be indicative of higher levels of lipid 
accumulation and storage compared to RCC4-VHL cells.
We next investigated the expression of proteins controlling the cellular labile iron pool in the 
isogenic cell line pair. The transferrin receptor (TFRC), which mediates iron uptake by 
receptor-mediated endocytosis, was more strongly expressed in VHL-restored cells (Fig. 
S3C), arguing against the possibility that differences in iron uptake mediate differential 
ferroptosis sensitivity in these cells. Furthermore, the gene coding for heme oxygenase 
HMOX1, the enzyme releasing iron during heme degradation, which has been shown to 
accelerate Erastin induced ferroptosis 31, did not show differential expression between the 
two cell lines (Fig. S3C). In contrast, expression of the lipoxygenase ALOX5, which 
catalyses the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-
eicosatetraenoic acid (HPETE) as part of the leukotriene pathway 41, was significantly 
lower in VHL-reconstituted cells (Fig. S3D). Moreover, ALOX5 mRNA also showed strong 
upregulation in ccRCC tumours compared to normal tissue (Fig. S3E), while TFRC mRNA 
was not deregulated (data not shown).
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To further explore differences between the cell lines that could be involved in determining 
their differential sensitivity towards induction of ferroptosis, we compared gene expression 
profiles from both cell lines 48. Gene set enrichment analysis (GSEA) revealed an 
upregulation of hallmark gene sets linked to oxidative phosphorylation and fatty acid 
metabolism in VHL-restored cells (Fig. S3F and 5E). Moreover, expression of carnitine 
palmitoyl-transferase 1A (CPT1A), the enzyme responsible for the transfer of acyl-groups 
from coenzyme A to carnitine for import into the mitochondrial matrix and subsequent 
degradation via β-oxidation, was strongly increased in VHL-reconstituted cells (Fig. 5F), 
further indicating that VHL-deficient and reconstituted cells differ in their ability to perform 
fatty acid degradation.
We therefore investigated whether inhibition of fatty acid metabolism altered ferroptosis 
sensitivity in ccRCC cells. Treatment with Etomoxir, an inhibitor of CPT1, or Oligomycin, 
an inhibitor of mitochondrial ATP-synthase, had no effect on cell number but fully restored 
the sensitivity of VHL-reconstituted cells towards inhibition of GSH synthesis by BSO (Fig. 
5G). In addition, exposure to these compounds together with low concentrations of BSO 
caused a synergistic reduction in cell number in VHL-deficient cells (Fig. 5G). Together, 
these results suggest that increased lipid storage and impaired fatty acid degradation as a 
consequence of inhibition of β-oxidation renders ccRCC cells highly dependent on cystine 
uptake and GSH synthesis to prevent the accumulation of lipid peroxides and maintain cell 
viability (Fig. 5H).
Inhibition of GSH synthesis blocks growth of renal tumours
As our results indicate that GSH biosynthesis and GPX function are important in ccRCC 
cells, we investigated GSH levels in human ccRCC tissue by histological staining. In normal 
kidney tissue, protein-bound GSH was mainly localised to the cytoplasm of epithelial cells 
within the proximal renal tubuli, while glomeruli showed low levels of staining (Fig. 6A). 
Furthermore, a clear distinction in GSH levels between high and low grade tumours was 
observed. While low-grade tumours (grade 1) showed lower levels of GSH staining 
compared to normal renal tissue, high-grade tumours (grade 3) displayed strongly elevated 
staining (Fig. 6B). Analysis of multiple tumour specimens confirmed that a larger proportion 
of high-grade tumours (grade 3 and 4) exhibit strong GSH staining compared to low-grade 
tumours (grade 1 and 2) (Fig. 6C), suggesting that the GSH pathway is highly important in 
advanced cancers.
Inactivation of VHL is a crucial event in the development of sporadic ccRCC. However, 
between 20% and 50% of human ccRCC tumours retain a functional VHL allele. We 
therefore expanded our panel of renal cancer cell lines to include three additional VHL 
mutant cell lines as well as four lines that retain functional VHL. In addition, a non-
malignant renal epithelial cell line (HK-2) was used. As expected, VHL mutant cell lines 
showed high normoxic levels of either HIF-2α alone (786-O and 769-P) or both HIF-1α and 
HIF-2α, while VHL wild type cells display low to undetectable levels of these proteins (Fig. 
S4A). VHL mutant cells also showed higher levels of AKT phosphorylation compared to 
wild type cells. In contrast, VHL wild type cells expressed higher levels of the MYC 
oncoprotein compared to VHL mutant lines while non-malignant HK-2 cells showed high 
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levels of HIF-1α, MYC and phospho-AKT, most likely due to the culture medium 
containing added growth factors (Fig. S4A). Nevertheless, all cell lines were highly sensitive 
towards depletion of glutamine or cystine (Fig. S4B). Moreover, no difference in the 
sensitivity between VHL wild type and mutant cell lines towards inhibitors of 
glutaminolysis (BPTES) or GSH synthesis (BSO) was detected (Fig. S4C). In addition, 
silencing of components of the GSH synthesis pathway as well as MYC, DHCR24, GPX3 or 
GPX4 also reduced the viability of most ccRCC cells (Fig. S4D). In all cases, ccRCC cells 
showed a higher sensitivity towards gene depletion compared to non-malignant HK-2 cells, 
indicating that the ccRCC cells have a higher dependency on GSH synthesis. These results 
also suggest that this dependency represents a general metabolic liability in this tumour type 
and can be induced not only through inactivation of VHL but also as a consequence of other 
oncogenic pathways, such as MYC activation.
Finally, we examined whether inhibition of GSH synthesis can interfere with renal 
tumourigenesis. We used a previously described model of renal cancer in which the human 
MYC protein is expressed in the mouse kidney following induction by the removal of 
doxycycline 44. Upon induction of tumour growth, GSH synthesis was inhibited by addition 
of BSO to the drinking water and tumour volume was assessed by magnetic resonance 
imaging (MRI) for three weeks. While BSO treatment did not affect the volume of normal 
kidneys in control mice, the volume of the cancer-bearing kidneys was reduced by at least 
30% (Fig. 6D and E). The reduction in tumour growth by BSO treatment was even more 
obvious when the weight of the tumour was assessed after 2 weeks of treatment (Fig. 6F). 
Moreover, histological sections of BSO treated tumours also showed a clear reversal of 
dysplasia and restoration of a more normal renal appearance (Fig. 6G).
Taken together, our results demonstrate that ccRCC cells are highly dependent on GSH 
synthesis in order to counteract lipid peroxidation and ferroptotic cell death. Moreover, we 
found that inhibition of GSH synthesis interferes with renal tumour growth and restores 
normal renal tissue morphology.
Discussion
Altered metabolic activity is a central feature of ccRCC, the most common form of kidney 
cancer. Here we show that ccRCC cells are highly susceptible to disruption of the GSH/GPX 
pathway, which prevents the accumulation of ROS, including lipid peroxides. We found that 
renal cancer cells are exquisitely sensitive to depletion of glutamine or cystine, two 
metabolites required for GSH biosynthesis. Glutamine supports multiple cellular metabolic 
processes, for example as a substrate for TCA cycle anaplerosis, a nitrogen source for 
nucleotide biosynthesis or as a substrate for reductive carboxylation to form citrate for 
lipogenesis 36, 37, 50. The dipeptide cystine is a major source of cellular cysteine, which is 
used for protein synthesis and GSH production.
We also used functional screening to identify metabolic genes that are essential for the 
survival of ccRCC cells. Unsurprisingly, several of these genes mapped to the glycolytic 
pathway as the metabolic changes driven by HIF1α activation are reminiscent of the 
Warburg effect 43 and deregulated expression of glycolytic enzymes are frequently found in 
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kidney cancer 39. Moreover, molecular characterisation of genetic and transcriptional 
alterations in ccRCC confirmed the strong association between deregulated glycolysis and 
patient survival in this disease 8. We also found an enzyme within the cholesterol 
biosynthesis pathway, namely DHCR24, to be essential for ccRCC cells. Cholesterol 
synthesis requires molecular oxygen and hypoxia-dependent regulation of this pathway has 
been described in yeast 27. Cholesterol and cholesterylesters are also required to form lipid 
droplets, lipid storage organelles that are a prominent feature in ccRCC 18, 40. Interestingly, 
isopentenyl pyrophosphate, an intermediate of the mevalonate pathway, is required for the 
maturation of the selenocysteine tRNA, which is essential for the production of 
selenocysteine-containing proteins, including GPX3 and GPX4 49, suggesting that high 
cholesterol synthesis may be a requirement in our system to maintain GPX3 and GPX4 
protein levels.
Inhibition of GSH biosynthesis in ccRCC cells, either by blocking cystine uptake or through 
inhibition of γ-glutamylcysteine synthetase by the small molecule inhibitors Erastin and 
BSO, respectively, triggered ferroptosis, an iron-dependent form of cell death 12. This was 
confirmed by our finding that the effect of Erastin or BSO on cell viability was blocked by 
treatment with fer-1, a free radical scavenger that can remove lipid peroxides from lipid 
membranes 12. Interestingly, we found that restoration of VHL function protected renal 
cancer cells from induction of cell death caused by depletion of GPX3 or GPX4 and also 
from the detrimental effect of Erastin and BSO. A previous study linked cystine deprivation 
in VHL-deficient renal cancers to induction of programmed necrosis via the tumour necrosis 
factor alpha (TNFα) 48. This study showed that depletion of components of the TNFα 
signalling pathway rendered VHL-deficient cancer cells insensitive to low doses of Erastin. 
We found that the lipid-antioxidant ferrostatin protected VHL-deficient renal cancer cells 
over a range of different doses of Erastin or BSO treatment, confirming that cell death 
induced by inhibition of GSH biosynthesis involves a ferroptotic mechanism.
Ferroptosis is linked to the accumulation of peroxidised lipids produced from PUFAs 
through enzymatic and non-enzymatic processes 52, 55. It has been shown that p53 induces 
ferroptosis by downregulating the expression of SLC7A11 29. However, we observed that 
VHL-restoration did not alter SLC7A11 expression levels, making it unlikely that the 
differential sensitivity of VHL-deficient and restored cells towards inhibition of GSH 
biosynthesis is caused by different levels of this transporter. Moreover, GSH levels were 
similar between both cell types but strongly reduced in response to Erastin or BSO 
treatment, indicating that the differential sensitivity is not caused by altered activity of the 
GSH synthesis pathway. Instead, it is likely that activation of oxidative metabolism in VHL-
restored cells, including increased metabolism of fatty acid by β-oxidation, results in a larger 
turnover of damaged lipids, thereby reducing the requirement for the GSH pathway for the 
detoxification of lipid peroxides. Indeed, inhibition of β-oxidation by treatment with the 
CPT1 inhibitor Etomoxir or Oligomycine, an inhibitor of mitochondrial ATP-synthase 
(complex V) completely restored ferroptosis induction in VHL-restored cells.
A recent lipidomic analysis revealed a large increase in triacylglycerides and cholesterol-
esters in ccRCC tumour tissue 42, suggesting that renal cancer cells may be particularly 
sensitive to ferroptosis due to their high lipid content. Although we did not observe major 
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differences in fatty acid composition between VHL-mutant and VHL-restored cells, we 
found that pVHL expression reduced the amount of LDs, the major storage organelle for 
neutral lipids, including triacylglycerides and cholesterol. Moreover, expression of ALOX5, 
the enzyme that controls the production of lipid peroxides from arachidonic acid, was 
repressed by pVHL. Consistent with a previous study linking increased expression of 
ALOX5 in ccRCC with enhanced expression of VEGF and high-grade disease 15, we found 
that ALOX5 mRNA is strongly overexpressed in ccRCC tumours compared to normal renal 
tissue. Induction of ALOX5 in renal cancer would increase the production of pro-
inflammatory leukotrienes 51. However, enhanced lipid peroxidation could also increase the 
dependency of cancer cells on the GSH/GPX system to prevent excess oxidative damage.
Somewhat surprisingly, we did not observe major differences in the sensitivity towards 
nutrient restriction or inhibition of GSH synthesis between VHL wild type and mutant 
ccRCC cell lines. One explanation for this finding could be the elevated levels of MYC 
expression that we observed in cell lines expressing functional pVHL. MYC is frequently 
overexpressed in cancer and promotes cell growth and proliferation by acting as a global 
modulator of gene expression. MYC and HIF have partially overlapping target genes and 
both transcription factors enhance the expression of glycolytic enzymes 21. MYC also 
induces widespread metabolic reprogramming in cancer cells, including activation of 
glucose and glutamine metabolism 11 and increased lipid synthesis 9. Experiments in 
transgenic mice have shown that MYC induces a profound lipogenic programme during 
renal cancer development 44. It is therefore likely that enhanced dependence on GSH 
biosynthesis is a general feature of renal cancer cells and linked to their highly glycolytic 
metabolism coupled with reduced fatty acid degradation through β-oxidation. Accordingly, 
we found that ccRCC cells showed an overall higher dependency on GSH biosynthesis 
enzymes compared to non-malignant cells, confirming the importance of this pathway in 
renal cancer.
We also observed that levels of GSH bound to proteins were enhanced in high-grade renal 
tumour tissue. This is in agreement with a previous study showing strong elevation of GSH 
in ccRCC tumours compared to normal tissue 32. Coupling of GSH is involved in the 
removal of damaged cellular components, including toxic protein-lipid adducts formed as a 
result of lipid peroxidation 10, by the biotransformation pathway.
Finally, our study demonstrates that inhibition of GSH biosynthesis by the γ-cysteine 
synthetase inhibitor BSO attenuates tumour formation in a MYC-dependent mouse model of 
renal carcinogenesis. In this system, enhanced proliferation of renal epithelial cells can 
already be seen after one week of MYC induction 44. Interestingly, we found that BSO 
caused a reduction in tumour growth when delivered before tumour onset. This is consistent 
with the previously reported data from a mouse model of breast cancer (MMTV-PyMT), 
where BSO alone could prevent carcinogenesis only when delivered before tumour onset, 
while combined inhibition of GSH and thioredoxin was required to reduce tumour burden at 
later stages 26.
Overall, the results presented here demonstrate that renal cancer cells are highly dependent 
on the GSH pathway for the detoxification of reactive oxygen radicals, including lipid 
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peroxides, and suggest that targeting components of this pathway could be an effective 
strategy for the treatment of this disease.
Material and Methods
Cell culture and reagents
RCC4, UMRC2, A498, 786-O, 769-P, CAKI1, CAKI2, TK10, A704, UMRC3, ACHN and 
UO31 cells as well as the non-tumorigenic proximal tubular HK-2 cell line were obtained 
from Cell Services (CRUK-LRI). VHL-isogenic ccRCC cell line pairs RCC4-EV and 
RCC4-VHL were obtained from William Kaelin Jr. (Dana Farber Cancer Institute, Boston, 
MA, USA) and used at low passage numbers. ccRCC cells were cultured in DMEM (Life 
Technologies) with 10% foetal bovine serum (FBS, Gibco), 4mM L-glutamine and 100U/ml 
Penicillin / 100μg/ml Streptomycin. HK-2 cells were cultured on collagen-coated cell 
culture dishes (BD Bioscience) in Keratinocyte-Serum-free medium (KSFM, Gibco) 
supplemented with 5ng/ml human recombinant EGF and 50ng/ml Bovine Pituitary Extract 
(BPE). All cells were cultured at 37°C in a humidified incubator at 5% CO2 and frequently 
tested to confirm absence of mycoplasma contamination. BPTES, BSO, H2O2, NAC, GSH, 
L-Cysteine hydrochloride, TEMPO, Erastin, BCNU and ferrostatin were obtained from 
Sigma-Aldrich.
Cell viability and cell number assays
Cells were seeded at low density and treated as indicated. After incubation, cells were fixed 
with 70% ethanol, stained with 0.01% crystal violet, washed and dried. For quantification, 
dye was extracted with 10% acetic acid and OD was measured at 550nm. For the 
determination of cell number, cells were stained with DAPI to visualize nuclei and analysed 
using an Acumen X3 laser scanning imaging cytometer (TTP Labtech) or an Operetta high 
content microscope (Perkin Elmer).
Nutrient depletion experiments
2000 cells/well were plated in 96-well plates in full growth medium. The next day, cells 
were washed with PBS before adding full medium or medium lacking glutamine or cystine, 
containing either solvent or GSH, NAC, L-cysteine or TEMPO, as indicated. Cell numbers 
were analysed 72h post depletion/supplementation.
Analysis of cellular respiration and extracellular acidification
10-35 x 103 cells/well were plated in sextuplets in regular culture medium in a 96-well XF 
culture plate. 16 hours later, cells were washed twice in PBS before changing to assay 
medium (Seahorse Biosciences) supplemented with 10mM sodium pyruvate and 25mM 
glucose with the pH adjusted to 7.4. Cells were incubated at 37°C in a CO2-free atmosphere 
for 1 hour and oxygen consumption rate (OCR) was determined using an XF96 Extracellular 
Flux Analyser (Software Version 1.4, Seahorse Biosciences, North Billerica, USA). During 
the experiment, 1.3μM oligomycin was injected, followed by 0.4 μM FCCP (Sigma) to 
measure the respiratory profile. OCRs were normalised to total protein content determined 
by sulforhodamine B staining.
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Cells were lysed in NP-40 lysis buffer (1% NP-40, 20mM Tris pH 7.5, 137mM NaCl, 1mM 
EGTA, 1mM DTT, 10% Glycerol, Protease-Inhibitor-Cocktail (Roche) and Phosphatase-
Inhibitor-Cocktail (Roche)). Proteins were separated on SDS-PAGE and blotted onto PVDF 
membrane (Immobilon). Membranes were blocked with 3% BSA, incubated with antibody 
solutions and signals were detected using ECL-reagent (Amersham). Antibodies for MYC 
(9E10, Sigma), phospho-AKT (S473, ), pan-AKT (both Cell Signaling Technology, #9271), 
HIF-1α (BD Biosciences, #610959), HIF-2α (Novus, #NB100-122), HA-tag (Covance, 
#MMS-101P) and HRP-conjugated anti-β-Actin (Sigma-Aldrich, #A3854) were used.
Analysis of patient data and survival analysis
Comparative gene expression analyses between ccRCC and normal kidney tissue were 
performed with Oncomine™ v4.5. Datasets used were from 56, 30, 24 and 3.
siRNA transfection and determination of cell number
The siRNA screen targeting 230 metabolic genes in renal cancer cells has been described 
before 17. Cell numbers were used to calculate z-scores based on the median absolute 
deviation (MAD) of the population 35.
For individual gene silencing, 2000 cells/well were reverse transfected with 37.5nM siRNA 
(Dharmacon siGENOME, SMARTpools) on 96-well plates. 96h post transfection, cells were 
fixed with 80% ice-cold ethanol. For the determination of cell number, cells were stained 
with DAPI to visualise nuclei and analysed using an Acumen X3 laser scanning imaging 
cytometer (TTP Labtech) or an Operetta high content microscope (Perkin Elmer). RNAi 
effects are represented as fold-change relative to scrambled-control transfection (CTRL). 
siUBB was used as positive control.
Detection of GSH using mass spectrometry
For the determination of GSH in cell extracts, adherent cells were washed with PBS and 
snap frozen in liquid N2. After addition of 250μl cold methanol/water (4/1, v/v), cells were 
scraped off and transferred into a tube. Water-soluble metabolites were extracted in a 530μl 
of a final mixture of methanol/water/chloroform (2/1.8/2, v/v/v) 5. After centrifugation, the 
Bligh/Dyer-upper phase was transferred into a new tube, evaporated for 30min at 35°C 
under a stream of nitrogen gas and taken to dryness in SpeedVac at room temperature. The 
dry residue was dissolved in CH3CN/5 mM NH4OAc (25/75, v/v) and measured by direct 
injection with a flow rate of 10 μl/min in negative ion mode using a Thermo Scientific™ Q-
Exactive™ quadrupole-Orbitrap mass spectrometer. Full mass scan (m/z 67-1000) at a 
resolution of 70 000 with automatic gain control target of 1x106 ions and a maximum ion 
injection time of 100 ms was used. Source ionization parameters were optimized with the 
spray voltage of 3.5 kV; transfer temperature of 320 °C; S-Lens level of 50; heater 
temperature of 325°C and Sheath gas 7.
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RNA extraction, reverse transcription and RT-qPCR
Total RNA was isolated using an RNeasy kit (Qiagen). 1-5μg of total RNA was used for first 
strand cDNA synthesis with SuperScript II Reverse Transcriptase and oligo-dT primers 
(Invitrogen). Real time PCR was performed with SYBR® Green PCR Master Mix (Applied 
Biosystems) using Quantitect primers (Qiagen) in an ABI PRISM 7900 Sequence Detection 
System (Applied Biosystems). All reactions were performed at least in duplicate. The 
relative amount of all mRNAs was calculated using the comparative CT method after 
normalization to ACTB or B2M.
Lipid peroxidation assay
For detection of lipid peroxidation, the Image-iT Lipid peroxidation kit (Life Technologies, 
Cat.no. C10445) was used. Cells were seeded in black 96-well plates with clear bottom and 
treated with Erastin for 24 hours. During the last 30min of incubation, 10μM of sensor was 
added to cultures. Cells were then washed 3 times with PBS and imaged immediately with a 
high throughput fluorescence microscope (Perkin Elmer, Operetta) using filters for FITC 
(Alexa488) and Texas Red (Alexa594). Signal intensities at 510nm and 590nm were used to 
quantify lipid peroxidation.
Lipid droplet staining
4000 cells/well were plated in 96-well plates and cultured for 48 hours before fixation with 
4% paraformaldehyde for 15 min, washed with PBS and stained for 30 minutes with 
0.1μg/ml Nile Red (Life Technologies) and 1μg/ml DAPI (Sigma) in PBS. Cells were 
washed three times in PBS and analysed using a Cellomics ArrayScan VT high content 
microscope (Thermo Fisher) with associated HCS studio:Cellomics Navigator Version 6.4.4 
software.
Histology
Paraffin-embedded 4μm thick tissue sections were deparaffinized and rehydrated. Antigen 
retrieval was performed with citrate buffer (pH 6.0) in a microwave oven for 30min. 
Endogenous peroxidase activity was blocked by incubating sections in 3% (v/v) hydrogen 
peroxide for 10min. Sections were blocked with 3% (w/v) BSA for 30min and incubated 
with an anti-GSH antibody (Abcam ab-19534), diluted 1:200 overnight at 4°C in a 
humidified chamber. Sections were washed in PBS and incubated with biotinylated 
secondary antibody followed by streptavidin-horseradish-peroxidase assay (Vector Labs, 
Dako). Reactions were developed using 3,3'-diaminobenzidine (Cell Signaling). Slides were 
counterstained with Gilmore 3 hematoxylin, dehydrated, cleared, and mounted with 
coverslips.
In vivo experiments
Transgenic mice GGT-TTA in S129 background and Tet-O-MYC in FVB/N background 
were bred to create a double-transgenic mouse line in which human MYC protein is 
expressed in the mouse kidney. MYC inactivation was achieved by supplementing the 
drinking water with 100 μg/mL doxycycline since birth. MYC activation at 4 weeks of age 
for both male and female mice was achieved by removal of doxycline from the drinking 
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water as previously described 44. All animal experiments were performed under the 
guidelines established by the Administrative Panel on Laboratory Animal Care at Stanford 
University. Sizes of animal cohorts were based on previous experiments 44. Animals were 
randomly assigned to the groups and no animals were excluded from the analysis. MYC 
inactivation was achieved by adding 100 μg/mL doxycycline to the drinking water and 
replacing it weekly. MYC activation was achieved by administering regular drinking water 
at 4 weeks of age. Glutathione pathway inhibition was examined for antitumor activity in 
vivo in the transgenic mouse model by adding 20mM of BSO (L-buthionine (S,R)-
sulfoximine); Sigma (Cat No B2515)) to the drinking water for treatment after 2 weeks of 
MYC activation.
Mice were visualised by magnetic resonance imaging (MRI) at 0, 7, and 14 days following 
treatment. Mice were sequentially imaged using a 7 Tesla MRI system at Stanford Small 
Animal Imaging Center. Kidney measurements were performed using T2-weighted axial 
image stacks using Osirix software to obtain the tumour volumes. Tissues were fixed in 10% 
(v/v) buffered formalin (Starplex Scientific) for 24 h, followed by transfer to 70% (v/v) 
ethanol. Samples were processed, embedded, and 5-μm paraffin sections were cut by 
Stanford Histology Services. H&E staining was performed using standard procedures. 
Kidneys are weighed when mice are sacrificed at the end of the experiment.
Statistical analysis
Graphs were generated using GraphPad Prism 6.0 (GraphPad software). All experiments 
have been performed independently at least twice with at least three biological replicates. 
Unless otherwise indicated, statistical significance of magnitude of changes between 
different conditions was calculated using the parametric two-tailed unpaired Student t-test. 
Statistical significance was defined as a p-value of less than 0.05. P-values are depicted as 
follows: *p≤0.05, **p≤0.01, ***p≤0.001 and ****p≤0.0001. n.s. = not significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Renal cancer cells are sensitive to glutamine and cystine depletion
A) RCC4, A498, UMRC2 and 769-P cells were seeded in full medium. After 24h, medium 
was replaced to normal medium or medium deprived of glutamine or cystine for 72h and cell 
numbers were determined. Values represent mean cell number ±SEM relative to full medium 
(n=3).
B) RCC4, A498, UMRC2 and 769-P cells were seeded in full medium. After 24h, cells were 
transferred to glutamine-free medium containing the different supplements and antioxidants. 
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Cells were fixed after 72h and cell numbers were determined. Values represent mean cell 
number ±SEM relative to full medium (n=3).
C) RCC4, A498, UMRC2 and 769-P cells were seeded in full medium. After 24h, cells were 
transferred to cystine-free medium containing the different supplements and antioxidants. 
Cells were fixed after 72h and cell numbers were determined. Values represent mean cell 
number ±SEM relative to full medium (n=3).
D) RCC4, A498, UMRC2 and 769-P cells were transfected with siRNA oligonucleotides 
targeting SLC7A11, SLC1A5, GSR or GLS or a non-targeting control (CTRL). Cell 
numbers were determined 96h post transfection. Values represent mean cell number ±SEM 
(n=3).
E) RCC4, A498, UMRC2, 786-O and 769-P cells were transfected with siRNA 
oligonucleotides targeting GCLC, GSS or a non-targeting control (CTRL). Cell number was 
determined 96h post transfection. Values represent mean cell number ±SEM (n=3).
F) RCC4 cells were transfected with siRNA oligonucleotides targeting SLC7A11, GSR, 
GCLC, GLS or a non-targeting control (CTRL). After 96 hours, cells were lysed and levels 
of reduced glutathione (GSH) were determined by mass spectrometry. Values represent 
mean peak intensity normalised to protein ±SEM (n=4).
*p≤0.05; **p≤0.01; ***p≤0.005; ****p≤0.001 unpaired two-tailed Student’s t-test.
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Figure 2. Functional siRNA screen identifies glutathione peroxidases as essential enzymes in 
renal cancer cells
A) RCC4, A498, UMRC2, 786-O and 769-P cells were transfected with siRNA 
oligonucleotides targeting 230 different metabolic enzymes, nutrient transporters and 
metabolic regulators. 96h post transfection, number of remaining cells was determined and 
used to calculate z-scores. Graph displays mean z-scores across all cell lines and selected 
genes are highlighted.
B) Table showing z-scores of selected genes in each of the five cell lines.
C) RCC4, A498, 786-O and 769-P cells were transfected with siRNA oligonucleotides 
targeting MYC, G6PD, DHCR24, GPX3 or GPX4 or a non-targeting control (RF). Cell 
numbers were determined 96h post transfection. Values represent mean cell number ±SEM 
(n=3).
*p≤0.05; **p≤0.01; ***p≤0.005; ****p≤0.001 unpaired two-tailed Student’s t-test.
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Figure 3. Inhibition of GSH synthesis induces ferroptosis in ccRCC cells
A) Diagram illustrating the mechanisms of GSH synthesis and induction of ferroptosis.
B) RCC4 and 786-O cells were treated with the indicated concentrations of Erastin or 
solvent (DMSO) either in the presence or absence of ferrostatin (fer-1) for 72h. Cell viability 
was determined by crystal violet staining. Values represent mean ±SEM relative to solvent-
treated controls (n=3).
C) RCC4 and 786-O cells were treated with the indicated concentrations of BSO or solvent 
(DMSO) either in the presence or absence of ferrostatin (fer-1) for 72h. Cell viability was 
determined by crystal violet staining. Values represent mean ±SEM relative to solvent-
treated controls (n=3).
D) RCC4 cells were transfected with siRNA oligonucleotides targeting SLC7A11, UBB or 
non-targeting controls (CTRL) and treated with 4 μM ferrostatin (fer-1) or solvent for 96 h. 
Cell viability was determined by crystal violet staining. Values represent mean ±SEM 
relative to solvent-treated controls (n=3).
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E) RCC4 cells were treated with the indicated concentrations of BSO or solvent (DMSO) 
for 24h. GSH levels were determined by mass spectrometry. Values represent mean ±SEM 
(n=2).
F) RCC4 and 786-O cells were treated with the indicated concentrations of BSO or solvent 
(DMSO) with or without different concentrations of hydrogen peroxide (H2O2) for 72 hours. 
Cell viability was determined by crystal violet staining. Values represent mean ±SEM 
relative to solvent-treated controls (n=3).
*p≤0.05; **p≤0.01; ***p≤0.005; ****p≤0.001 unpaired two-tailed Student’s t-test.
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Figure 4. Restoration of pVHL function leads to ferroptosis resistance in ccRCC cells
A) Isogenic RCC4 cells were generated by expression of functional VHL (RCC4-VHL) or 
empty vector (RCC4-EV) 33. Analysis of protein expression shows reduced expression of 
HIF-1α and HIF-2α in VHL-restored cells. Expression of HA-tagged pVHL was also 
confirmed. β-Actin was used as loading control.
B) mRNA levels of VEGFA and PDHK1 in isogenic RCC4 cell lines. Values represent mean 
±SD relative to RCC4-EV and are normalised to B2M (n=2).
C) Phosphorylation of AKT (serine 473) and pS6 (serines 235 and 236) was determined by 
immunoblotting using phospho-specific antibodies.
D) Oxygen consumption rates (OCR) were determined in RCC4-EV and RCC4-VHL cells 
using a Seahorse Bioanalyzer and used to calculate basal respiration, maximal respiration in 
the presence of FCCP, spare respiratory capacity and ATP-dependent respiration. Values 
represent mean ±SEM of 6 replicates.
E) Genes showing differential essentiality in RCC4-EV and RCC4-VHL cells (Δz-score≥1).
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F) RCC4-EV and RCC4-VHL cells were treated with 1μM Erastin or solvent (DMSO) in 
the presence or absence of 4μM ferrostatin (fer-1) for 72h. Cell viability was determined by 
crystal violet staining. Values represent mean ±SEM relative to solvent-treated controls 
(n=3).
G) RCC4-EV and RCC4-VHL cells were treated with the indicated concentrations of BSO 
or solvent (DMSO) in the presence or absence of ferrostatin (fer-1) for 72h. Cell viability 
was determined by crystal violet staining. Values represent mean ±SEM relative to solvent 
treated controls (n=3).
H) RCC4-EV and RCC4-VHL cells were treated with the indicated concentrations of BSO 
or solvent (DMSO) together with increasing concentrations of H2O2 for 72 hours. Cell 
viability was determined by crystal violet staining. Values represent mean ±SEM relative to 
solvent-treated controls (n=3).
*p≤0.05; **p≤0.01; ***p≤0.005; ****p≤0.001 unpaired two-tailed Student’s t-test.
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Figure 5. Induction of ferroptosis in ccRCC cells is mediated by lipid peroxidation
A) RCC4-EV cells were treated with the indicated concentrations of Erastin for 24h. Lipid 
peroxidation was determined using the BODIPY 581/591 C11 reagent. Values represent 
mean ±SEM relative to solvent-treated controls (n=3).
B) Relative amounts of saturated (SFA), mono-unsaturated (MUFA) and poly-unsaturated 
(PUFA) fatty acids in RCC4-EV and RCC4-VHL cells. Values represent mean percentages 
±SEM of the total fatty acid content (n=3).
C) RCC4-EV and RCC4-VHL cells were cultured for 48 hours in full medium before 
fixation and staining with Nile Red to detect lipid droplets (LD). Cells were imaged using a 
Cellomics high content microscope.
D) Average numbers of LDs per cell, average LD size (pixel per LD) and average LD 
staining intensity (fluorescence intensity units, FIU). Values represent mean ± SEM (n=3).
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E) GSEA results of expression data from RCC4-EV and RCC4-VHL cells from 48. 
Enrichment plots for two gene sets from the hallmark database associated with oxidative 
phosphorylation and fatty acid metabolism are shown.
F) Expression of CPT1A in RCC4-EV and RCC4-VHL cells. Values represent mean ±SEM 
relative to RCC4-EV and are normalised to ACTB (n=3).
G) RCC4-EV and RCC4-VHL cells were treated with the indicated concentrations of BSO 
or solvent (DMSO) together with 100 μM of Etomoxir or 2 μM of Oligomycin for 72h. Cell 
viability was determined by crystal violet staining. Values represent mean ±SEM relative to 
solvent-treated controls (n=7).
H) Diagram illustrating the link between induction of β-oxidation and oxidative 
phosphorylation (OxPhos) and protection from ferroptosis by pVHL.
*p≤0.05; **p≤0.01; ***p≤0.005; ****p≤0.001 unpaired two-tailed Student’s t-test.
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Figure 6. Inhibition of GSH synthesis blocks renal tumour growth
A) Detection of GSH in normal kidney tissue. Corresponding sections of normal renal cortex 
were stained for in situ protein-bound GSH. H&E staining is shown for comparison. 
G=glomerulus, PT=proximal tubulus, DT=distal tubulus.
B) Detection of in situ protein-bound GSH in tissue from ccRCC patients. Representative 
sections of grade 1 and grade 3 tumours are shown with corresponding H&E staining for 
comparison. Insets indicate nuclear morphology of grade 1 and grade 3 tumours.
C) Quantification of GSH staining in 12 low- and 25 high-grade ccRCC tumours. Relative 
staining intensities were scored in a blinded fashion. Statistical comparison was performed 
using a two-tailed Chi-square test with 95% confidence intervals.
D) Transgenic mice with the γ-glutamyl transferase (GGT) promoter driving the tetracycline 
transactivator protein (tTA) and MYC under the control of the tetracycline-responsive 
element (MYC-GGT-tTA) were treated with 100 μg/ml doxycycline in the drinking water. 
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To induce the formation of renal cell carcinomas (RCC), mice were shifted to normal 
drinking water to induce expression of MYC. After 2 weeks of MYC activation, one cohort 
of mice was treated with 20 mM BSO in the drinking water. Kidney volumes were 
monitored by magnetic resonance imaging (MRI) over a period of 3 weeks (BSO-treated) 
and compared to untreated MYC-expressing mice (untreated RCC) and kidneys from normal 
controls (normal kidney). Values show mean kidney volume ±SEM (n=3).
E) Representative MRI images indicating differences in kidney volume in BSO treated 
animals.
F) Kidney weight at endpoint of D in the 3 cohorts.
G) Representative histological sections of kidneys at endpoint of D illustrating the 
restoration of normal tissue morphology by BSO treatment.
****p≤0.001 unpaired two-tailed Student’s t-test.
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